Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Approvals Action
Menarini adds to COPD list
A Menarini has won registration for new chronic obstructive pulmonary disease treatment Brimica Genuair two months out from its consideration by the PBAC.
Special Report
Insulin battle is on the doorstep
With a swag of new insulins on the horizon, including a biosimilar competitor for market leader Lantus, the diabetes market appears to be in for a serious shake-up.
Special Report
Your guide to the July PBAC
Your full rundown on the July PBAC meeting agenda, sorted into major and minor submissions plus alpha order of indication.
Pipeline Monitor
Market beckons for another melanoma drug
BMS' Opdivo in melanoma, new anticoagulant Lixiana, an antidote for Pradaxa and Amgen's PCSK9 inhibitor all made important steps towards market during the week as did Biogen and AbbVie's MS drug Zinbryta.